Trump Renews Push for Most-Favored-Nation Drug Pricing. What It All Means
Trump Says Prescription Drug Prices Set To Drop By 30% To 80% 'Almost Immediately' Thanks To 'Most Favored Nation' Plan, Mark Cuban Urges President To 'Force Transparency'
Kamada (KMDA) Q1 Earnings Preview: What You Should Know Beyond the Headline Estimates
Sidoti Initiates Kamada(KMDA.US) With Hold Rating, Announces Target Price $13
Earnings Preview: Kamada to Report Financial Results Pre-market on May 14
Kamada | 6-K: Report of foreign private issuer (related to financial reporting)
Kamada to Announce First Quarter 2025 Financial Results on May 14, 2025
Kamada to Announce First Quarter 2025 Financial Results on May 14, 2025 – Company to Host Conference Call at 8:30am ET
Kamada Announces Launch of Post-marketing Research Program for CYTOGAM
Express News | Kamada Launches Post-Marketing Research Program For CYTOGAM
Kamada Announces Launch of a Comprehensive Post-Marketing Research Program for CYTOGAM
Top Premarket Decliners
AI replacing animal experiments? A message from the FDA has left "monkey breeders" feeling devastated, and experts state that "we are still far from the stage of implementation."
① The news that the USA FDA has publicly stated it will gradually replace animal testing requirements has led to an increase in the stock prices of AI pharmaceutical companies, impacting traditional drug evaluation CRO companies; ② Some believe this action represents a trend in Industry development. However, others believe that it is far from being implementable.
Kamada Declares $0.20 Dividend
Express News | Kamada Updates on Withholding Tax Procedures on Previously Announced Special Cash Dividend to Shareholders
Press Release: Kamada Updates on Withholding Tax Procedures on Previously Announced Special Cash Dividend to Shareholders
Benchmark Co. Initiates Kamada(KMDA.US) With Buy Rating, Announces Target Price $15
Kamada Initiated at Buy by Benchmark
Benchmark Initiates Kamada at Buy With $15 Price Target
Express News | Kamada Ltd: Intends to Submit Approval Applications for New Site to U.S. FDA and European Medicines Agency During Second Half of 2025